Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.61 |
| ▸ | TSHR | P16473 | 5/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13936399 | 0.85 | KMT2A (0.73) | KMT2AKDM4EPOLBATMHSD17B10 | |
| SCHEMBL1640485 | 0.83 | KMT2A (0.71) | KMT2AKDM4EPOLBATMHSD17B10 | |
| SCHEMBL10165944 | 0.83 | KMT2A (0.71) | KMT2AKDM4EPOLBATMHSD17B10 | |
| SCHEMBL4341926 | 0.83 | KMT2A (0.71) | KMT2AKDM4EPOLBATMHSD17B10 | |
| SCHEMBL5442803 | 0.83 | KMT2A (0.71) | KMT2AKDM4EPOLBATMHSD17B10 | |
| SCHEMBL29655205 | 0.83 | KMT2A (0.71) | KMT2AKDM4EPOLBATMHSD17B10 | |
| SCHEMBL12811737 | 0.83 | KMT2A (0.71) | KMT2AKDM4EPOLBATMHSD17B10 | |
| SCHEMBL7522563 | 0.83 | KDM4E (0.67) | KDM4EHSD17B10TSHRMAPK1HPGD | |
| SCHEMBL10502377 | 0.81 | KMT2A (1.00) | KMT2AKDM4EPOLBATMHSD17B10 | |
| SCHEMBL10965735 | 0.81 | KMT2A (0.69) | KMT2AKDM4EPOLBATMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888505-B2 | 6,7-dihydrobenzimidazo[1,2-c]quinazolin-6-one carboxylic acids, their esters, and methods of synthesis thereof | Crysoptix, KK (JP) | 2011-02-15 | — | — | US | disclosed |
| US-7888505-B2 | 6,7-dihydrobenzimidazo[1,2-c]quinazolin-6-one carboxylic acids, their esters, and methods of synthesis thereof | Crysoptix, KK (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20100047477-A1 | 6,7-Dihydrobenzimidazo[1,2-c]Quinazolin-6-One Carboxylic Acids, their Esters, and Methods of Synthesis Thereof | CRYSOPTIX KK (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100047477-A1 | 6,7-Dihydrobenzimidazo[1,2-c]Quinazolin-6-One Carboxylic Acids, their Esters, and Methods of Synthesis Thereof | CRYSOPTIX KK (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-0972773-A1 | 2-Oxadiazolyl- or 2-thiadiazolyl-phenylcarbamate and -phenylurea derivatives, their preparation and their use as intermediates | GLAXO GROUP LIMITED (GB) | 2000-01-19 | — | — | EP | disclosed |
| EP-0640081-B1 | SUBSTITUTED PHENYLCARBAMATES AND PHENYLUREAS, THEIR PREPARATION AND THEIR USE AS 5-HT4 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2000-01-12 | — | — | EP | disclosed |
| US-5618827-A | TREATING GASTROINTESTINAL, URINARY, CARDIOVASCULAR, CENTRAL NERVOUS SYTEM DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-04-08 | — | — | US | disclosed |
| EP-0640081-A1 | SUBSTITUTED PHENYLCARBAMATES AND PHENYLUREAS, THEIR PREPARATION AND THEIR USE AS 5-HT ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993020071-A1 | SUBSTITUTED PHENYLCARBAMATES AND PHENYLUREAS, THEIR PREPARATION AND THEIR USE AS 5-HT ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047477-A1 | 6,7-Dihydrobenzimidazo[1,2-c]Quinazolin-6-One Carboxylic Acids, their Esters, and Methods of Synthesis Thereof | SCN7A, CA7, HCN3 | KMT2A 2767/4885KDM4E 3428/4885POLB 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.